PE ratio relative to earnings growth — is the valuation justified?
| Symbol | Company | PEG | P/E | Growth | vs VRTX |
|---|---|---|---|---|---|
| NVO | Novo Nordisk A/S | 0.09 | 1.8 | 20.6% | -97% |
| INCY | Incyte Corporation | 0.24 | 15.1 | 62.7% | -93% |
| BMRN | BioMarin Pharmaceutical Inc. | 1.52 | 40.8 | 26.9% | -56% |
| REGN | Regeneron Pharmaceuticals, Inc. | 2.85 | 16.3 | 5.7% | -18% |
| ILMN | Illumina, Inc. | 8.18 | 34.4 | 4.2% | +135% |